GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heart Test Laboratories Inc (NAS:HSCS) » Definitions » COGS-to-Revenue

Heart Test Laboratories (Heart Test Laboratories) COGS-to-Revenue : 0.33 (As of Jan. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Heart Test Laboratories COGS-to-Revenue?

Heart Test Laboratories's Cost of Goods Sold for the three months ended in Jan. 2024 was $0.01 Mil. Its Revenue for the three months ended in Jan. 2024 was $0.02 Mil.

Heart Test Laboratories's COGS to Revenue for the three months ended in Jan. 2024 was 0.33.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Heart Test Laboratories's Gross Margin % for the three months ended in Jan. 2024 was 66.67%.


Heart Test Laboratories COGS-to-Revenue Historical Data

The historical data trend for Heart Test Laboratories's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heart Test Laboratories COGS-to-Revenue Chart

Heart Test Laboratories Annual Data
Trend Apr20 Apr21 Apr22 Apr23
COGS-to-Revenue
0.72 0.42 0.57 0.60

Heart Test Laboratories Quarterly Data
Apr20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 - - 0.50 0.33

Heart Test Laboratories COGS-to-Revenue Calculation

Heart Test Laboratories's COGS to Revenue for the fiscal year that ended in Apr. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.003 / 0.005
=0.60

Heart Test Laboratories's COGS to Revenue for the quarter that ended in Jan. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.005 / 0.015
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heart Test Laboratories  (NAS:HSCS) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Heart Test Laboratories's Gross Margin % for the three months ended in Jan. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.005 / 0.015
=66.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Heart Test Laboratories COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Heart Test Laboratories's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Heart Test Laboratories (Heart Test Laboratories) Business Description

Traded in Other Exchanges
N/A
Address
550 Reserve Street, Suite 360, Southlake, TX, USA, 76092
Heart Test Laboratories Inc is a medical technology company focused on applying innovative AI-based technology to an ECG to expand and improve an ECG's clinical usefulness. The objective of the company is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings.
Executives
David R. Wells director 2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405
Bruce Bent director 750 BONHAM PARKWAY, LANTANA TX 76226
Mark T Hilz director, officer: See Remarks 3301 DAKOTA DRIVE, NORTHLAKE TX 76226
Patrick Kanouff director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Brian Szymczak director 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Danielle Watson officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092
Andrew Simpson director, officer: See Remarks 550 RESERVE STREET, SUITE 360, SOUTHLAKE TX 76092